天眼查App显示,2025年5月27日,“咪唑并吡啶类化合物及其制备方法和应用”正式进入专利公布阶段。申请人为上海复旦张江生物医药股份有限公司,该项药物化学专利涉及药物合成技术领域。据专利信息显示,该发明显著优化了取代的咪唑并[1,2-a]吡啶-2-基酰胺类化合物的合成工艺,具有收率高、操作简便的优势,适用于工业化生产。发明人为成明、浦宇、蒋晓晟、薛逸君、蒋剑平。 “本发明公开了一种咪唑并吡啶...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.